Krish S. Krishnan net worth and biography

Krish Krishnan Biography and Net Worth

Suma Krishnan has 25 years of drug development experience and has delivered on multiple gene therapy programs from discovery to the clinic as Head of Therapeutics at Intrexon Corporation (NYSE: XON). Previously, she led the discovery, development, and approval of Vyvanse™ (blockbuster drug to treat ADHD) as SVP, Product Development at New River Pharmaceuticals. Prior to that, Suma advanced approval of Adderall XR® and Fosrenol® at Shire. She began her career as a discovery scientist for Janssen Pharmaceuticals, Inc. Suma has over 20 publications and 20 issued US patents. She received her Master of Science in Organic Chemistry from Villanova University, an M.B.A. from Institute of Management and Research, and an undergraduate degree in Organic Chemistry from Ferguson University.

What is Krish S. Krishnan's net worth?: The estimated net worth of Krish S. Krishnan is at least $273.21 million as of January 17th, 2023. Ms. Krishnan owns 1,741,539 shares of Krystal Biotech stock worth more than $273,212,638 as of April 27th. This net worth evaluation does not reflect any other assets that Ms. Krishnan may own. Additionally, Ms. Krishnan receives an annual salary of $1,070,000.00 as CEO at Krystal Biotech. Additionally, Ms. Krishnan receives an annual salary of $789,920.00 as CEO at Krystal Biotech. Learn More about Krish S. Krishnan's net worth.
How old is Krish S. Krishnan?: Ms. Krishnan is currently 59 years old. There are 2 older executives and no younger executives at Krystal Biotech. Learn More on Krish S. Krishnan's age.
What is Krish S. Krishnan's salary?: As the CEO of Krystal Biotech, Inc., Ms. Krishnan earns $789,920.00 per year. The highest earning executive at Krystal Biotech is Mr. Krish S. Krishnan M.B.A., M.S., Founder, Chairman, President & CEO, who commands a salary of $1,070,000.00 per year. Learn More on Krish S. Krishnan's salary.
How do I contact Krish S. Krishnan?: The corporate mailing address for Ms. Krishnan and other Krystal Biotech executives is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. Krystal Biotech can also be reached via phone at (412) 586-5830 and via email at [email protected]. Learn More on Krish S. Krishnan's contact information.
Has Krish S. Krishnan been buying or selling shares of Krystal Biotech?: Krish S. Krishnan has not been actively trading shares of Krystal Biotech in the last ninety days. Most recently, Krish S. Krishnan sold 22,149 shares of the business's stock in a transaction on Tuesday, January 17th. The shares were sold at an average price of $80.77, for a transaction totalling $1,788,974.73. Following the completion of the sale, the chief executive officer now directly owns 1,741,539 shares of the company's stock, valued at $140,664,105.03. Learn More on Krish S. Krishnan's trading history.
Who are Krystal Biotech's active insiders?: Krystal Biotech's insider roster includes Daniel Janney (Director), Krish Krishnan (CEO), Suma Krishnan (COO), Kathryn Romano (CAO), and Dino Rossi (Director). Learn More on Krystal Biotech's active insiders.
Are insiders buying or selling shares of Krystal Biotech?: In the last year, insiders at the sold shares 13 times. They sold a total of 279,680 shares worth more than $32,580,188.72. The most recent insider tranaction occured on March, 11th when insider Suma Krishnan sold 25,000 shares worth more than $4,274,000.00. Insiders at Krystal Biotech own 14.1% of the company. Learn More about insider trades at Krystal Biotech.
Information on this page was last updated on 3/11/2024.

Krish S. Krishnan Insider Trading History at Krystal Biotech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/17/2023	Sell	22,149	$80.77	$1,788,974.73	1,741,539
1/4/2023	Sell	3,748	$80.08	$300,139.84	1,763,688
12/16/2022	Sell	10,572	$80.10	$846,817.20	1,777,146
11/8/2022	Sell	966	$80.05	$77,328.30	1,787,722
11/18/2019	Sell	22,121	$52.33	$1,157,591.93	2,024,567
11/15/2019	Sell	27,879	$50.41	$1,405,380.39	2,024,567
10/18/2018	Buy	25,000	$20.00	$500,000.00
3/19/2018	Buy	50,000	$11.00	$550,000.00

Krish S. Krishnan Buying and Selling Activity at Krystal Biotech

Krystal Biotech Company Overview

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Today's Range

Now: $156.88

$153.79

$158.93

50 Day Range

MA: $164.33

$108.01

$180.42

2 Week Range

Now: $156.88

$82.09

$189.97

Volume

165,898 shs

Average Volume

246,093 shs

Market Capitalization

$4.47 billion

P/E Ratio

1,961.25

Dividend Yield

N/A

Beta

0.85

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>

Krish Krishnan Biography and Net Worth

What is Krish S. Krishnan's net worth?

How old is Krish S. Krishnan?

What is Krish S. Krishnan's salary?

How do I contact Krish S. Krishnan?

Has Krish S. Krishnan been buying or selling shares of Krystal Biotech?

Who are Krystal Biotech's active insiders?

Are insiders buying or selling shares of Krystal Biotech?